Sino Biopharmaceutical (HK:1177) has released an update.
Sino Biopharmaceutical reported a robust third quarter in 2024, with a 14.3% increase in revenue to approximately RMB5.47 billion and a staggering 123.4% rise in profit attributable to owners. The company’s focus on innovation and accelerated market launches in key therapeutic areas continues to drive its impressive financial growth.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.
